Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle
Andreas Rank, Oliver Weigert, Helmut OstermannMedizinische Klinik III – Grosshadern, Klinikum der Ludwig Maximilians-Universitaet Munich, Munich, GermanyAbstract: Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the peripheral circulation have been recog...
Guardado en:
Autores principales: | Andreas Rank, Oliver Weigert, Helmut Ostermann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/22dad4fc01334c3e9df59507aa98af48 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
por: Barış YILMAZ, et al.
Publicado: (2021) -
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Lawrence Rice
Publicado: (2009) -
Emerging Concepts in Immune Thrombotic Thrombocytopenic Purpura
por: Aicha Laghmouchi, et al.
Publicado: (2021) -
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
por: Ara Metjian, et al.
Publicado: (2009) -
THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
por: Zahid Farooq Baig, et al.
Publicado: (2018)